Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PNCA3
MCID: PNC095
MIFTS: 33

Pancreatic Cancer 3 (PNCA3)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Pancreatic Cancer 3

About this section

MalaCards integrated aliases for Pancreatic Cancer 3:

Name: Pancreatic Cancer 3 57 74 29 6
Pancreatic Cancer, Susceptibility to, 3 57 13
Pnca3 57 74
Cancer, Pancreatic, Susceptibility to, Type 3 40

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases
Anatomical: Endocrine diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 613348
MeSH 44 D010190
MedGen 42 C3150547
Sources

Summaries for Pancreatic Cancer 3

About this section
UniProtKB/Swiss-Prot : 74 Pancreatic cancer 3: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 3, also known as pancreatic cancer, susceptibility to, 3, is related to zollinger-ellison syndrome and fanconi anemia, complementation group n. An important gene associated with Pancreatic Cancer 3 is PALB2 (Partner And Localizer Of BRCA2). The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and breast, and related phenotype is cardiovascular system.

More information from OMIM: 613348
Sources

Related Diseases for Pancreatic Cancer 3

About this section

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer 3 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 9.8
2 fanconi anemia, complementation group n 9.3 PALB2 DCTN5
3 tracheoesophageal fistula 9.1 PALB2 DCTN5

Sources

Symptoms & Phenotypes for Pancreatic Cancer 3

About this section

Clinical features from OMIM:

613348

MGI Mouse Phenotypes related to Pancreatic Cancer 3:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 8.8 DCTN5 GDNF PALB2
Sources

Drugs & Therapeutics for Pancreatic Cancer 3

About this section

Drugs for Pancreatic Cancer 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Pancrelipase Approved, Investigational Phase 2 53608-75-6
4
Fluorouracil Approved Phase 2 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
6
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
7
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
8 Antineoplastic Agents, Phytogenic Phase 2
9 Albumin-Bound Paclitaxel Phase 2
10 pancreatin Phase 2
11 Tubulin Modulators Phase 2
12 Anti-Infective Agents Phase 2
13 Immunosuppressive Agents Phase 2
14 Antimitotic Agents Phase 2
15 Antiviral Agents Phase 2
16 Antimetabolites, Antineoplastic Phase 2
17 Antimetabolites Phase 2
18 Immunologic Factors Phase 2
19 Mitogens Phase 2
20 Antineoplastic Agents, Immunological Phase 2
21
Sulindac Approved, Investigational Phase 1 38194-50-2 5352 1548887
22 Analgesics Phase 1
23 Anti-Inflammatory Agents Phase 1
24 Cyclooxygenase Inhibitors Phase 1
25 Anti-Inflammatory Agents, Non-Steroidal Phase 1
26 Peripheral Nervous System Agents Phase 1
27 Analgesics, Non-Narcotic Phase 1
28
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
29 Protein Kinase Inhibitors Phase 1
30 Antirheumatic Agents Phase 1
31
Oxaliplatin Approved, Investigational Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
32
leucovorin Approved Early Phase 1 58-05-9 143 6006
33
Levoleucovorin Approved, Investigational Early Phase 1 68538-85-2
34
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037
35
Calcium Approved, Nutraceutical Early Phase 1 7440-70-2 271
36 topoisomerase I inhibitors Early Phase 1
37 Topoisomerase Inhibitors Early Phase 1
38 Folate Early Phase 1
39 Vitamin B9 Early Phase 1
40 Calcium, Dietary Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer Completed NCT01298011 Phase 2 Gemcitabine and Abraxane
2 A Randomized, Placebo-controlled, Blinded Phase II Study of Huachansu & Gemcitabine in Pancreatic Cancer Completed NCT00837239 Phase 2 Gemcitabine;HuaChanSu;Placebo
3 Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System Recruiting NCT03185988 Phase 2 chemotherapy in combination with trastuzumab for arm1;chemotherapy in combination with trastuzumab for arm2;chemotherapy in combination with trastuzumab for arm3;chemotherapy in combination with trastuzumab for arm4
4 Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac Completed NCT01515137 Phase 1 Erlotinib;Erlotinib plus sulindac;Placebo
5 Biomarkers Study in Pancreatic Cancer Unknown status NCT01666184
6 Comparison of the Diagnostic Accuracy Between Base and Cover Slide Smear After Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer Completed NCT02190071
7 Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study Completed NCT01992705 Early Phase 1 -Oxaliplatin 85 mg/m2 IV on Day 1;-Irinotecan 180 mg/m2 IV on Day 1;-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
8 The Effect of a 10-day Course of Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Locally Advanced and Advanced Pancreatic Cancer, a Randomized Phase II Study. Completed NCT00324428

Search NIH Clinical Center for Pancreatic Cancer 3

Sources

Genetic Tests for Pancreatic Cancer 3

About this section

Genetic tests related to Pancreatic Cancer 3:

# Genetic test Affiliating Genes
1 Pancreatic Cancer 3 29 PALB2
Sources

Anatomical Context for Pancreatic Cancer 3

About this section

MalaCards organs/tissues related to Pancreatic Cancer 3:

41
Pancreas, Liver, Breast
Sources

Publications for Pancreatic Cancer 3

About this section

Articles related to Pancreatic Cancer 3:

(show all 21)
# Title Authors PMID Year
1
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 8 71
19264984 2009
2
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 8
25356972 2015
3
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. 8
17200668 2007
4
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 38
30306620 2019
5
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. 38
31230047 2019
6
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. 38
27893535 2018
7
Inferoposterior duodenal approach for laparoscopic pancreaticoduodenectomy. 38
26877619 2016
8
Inferior vena caval thrombosis complicating pyogenic liver abscess after pancreatoduodenectomy: a case report. 38
26380170 2015
9
Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies. 38
24387841 2014
10
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. 38
24419109 2014
11
Vitamin D status and the risk of pancreatic cancer: a meta-analysis. 38
24033964 2013
12
Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples. 38
21547133 2011
13
Adjuvant therapy of pancreatic cancer. 38
20397913 2010
14
Diagnosis of pancreatic cancer by cytology and telomerase activity in exfoliated cells obtained by pancreatic duct brushing during endoscopy. 38
17548257 2007
15
Serum IgG4 concentrations in pancreatic and biliary diseases. 38
16426597 2006
16
Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. 38
12955450 2004
17
Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. 38
15039161 2004
18
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. 38
14576500 2003
19
Magnetic resonance study of the pancreatic duct. 38
10348928 1999
20
[Acute cholecystitis after placement of biliary endoprosthesis. Treatment by percutaneous cholecystostomy]. 38
2966350 1988
21
Diagnostic significance of bile cytology in obstructive jaundice. 38
6748391 1984
Sources

Variations for Pancreatic Cancer 3

About this section

ClinVar genetic disease variations for Pancreatic Cancer 3:

6 (show all 47)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PALB2 NM_024675.3(PALB2): c.106C> T (p.Gln36Ter) single nucleotide variant Pathogenic rs757369748 16:23649393-23649393 16:23638072-23638072
2 PALB2 NM_024675.3(PALB2): c.1027C> T (p.Gln343Ter) single nucleotide variant Pathogenic rs180177097 16:23646840-23646840 16:23635519-23635519
3 PALB2 NM_024675.3(PALB2): c.1314del (p.Phe440fs) deletion Pathogenic rs515726065 16:23646553-23646553 16:23635232-23635232
4 PALB2 PALB2: c.3202-?_*297del (p.Gly1068_Ser1186delins45) deletion Pathogenic 16:23614483-23619333 16:23603162-23608012
5 PALB2 NM_024675.3(PALB2): c.3497del (p.Gly1166fs) deletion Pathogenic rs180177138 16:23614844-23614844 16:23603523-23603523
6 PALB2 NM_024675.3(PALB2): c.509_510del (p.Arg170fs) deletion Pathogenic rs515726123 16:23647358-23647359 16:23636036-23636037
7 PALB2 NM_024675.3(PALB2): c.72del (p.Arg26fs) deletion Pathogenic rs180177142 16:23649427-23649427 16:23638106-23638106
8 PALB2 NM_024675.3(PALB2): c.755_756CT[1] (p.Leu253fs) short repeat Pathogenic rs180177092 16:23647109-23647110 16:23635788-23635789
9 PALB2 NM_024675.3(PALB2): c.1240C> T (p.Arg414Ter) single nucleotide variant Pathogenic rs180177100 16:23646627-23646627 16:23635306-23635306
10 PALB2 NM_024675.3(PALB2): c.3549C> A (p.Tyr1183Ter) single nucleotide variant Pathogenic rs118203998 16:23614792-23614792 16:23603471-23603471
11 PALB2 NM_024675.3(PALB2): c.2834+1G> T single nucleotide variant Pathogenic/Likely pathogenic rs587776419 16:23635329-23635329 16:23624008-23624008
12 PALB2 NM_024675.3(PALB2): c.3256C> T (p.Arg1086Ter) single nucleotide variant Pathogenic/Likely pathogenic rs587776527 16:23619279-23619279 16:23607958-23607958
13 PALB2 NM_024675.3(PALB2): c.3116del (p.Asn1039fs) deletion Pathogenic/Likely pathogenic rs180177133 16:23625410-23625410 16:23614089-23614089
14 PALB2 NM_024675.3(PALB2): c.168_171TTGT[1] (p.Gln60fs) short repeat Pathogenic/Likely pathogenic rs180177143 16:23649207-23649210 16:23637886-23637889
15 PALB2 PALB2: c.2515-1G> T single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs587776417 16:23640597-23640597 16:23629276-23629276
16 PALB2 NM_024675.3(PALB2): c.3549C> G (p.Tyr1183Ter) single nucleotide variant Pathogenic/Likely pathogenic rs118203998 16:23614792-23614792 16:23603471-23603471
17 PALB2 NM_024675.3(PALB2): c.1010T> C (p.Leu337Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs45494092 16:23646857-23646857 16:23635536-23635536
18 PALB2 NM_024675.3(PALB2): c.11C> T (p.Pro4Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs45619737 16:23652468-23652468 16:23641147-23641147
19 PALB2 NM_024675.3(PALB2): c.3251C> T (p.Ser1084Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs62625271 16:23619284-23619284 16:23607963-23607963
20 PALB2 NM_024675.3(PALB2): c.2773G> C (p.Val925Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs180177125 16:23635391-23635391 16:23624070-23624070
21 PALB2 NM_024675.3(PALB2): c.2816T> G (p.Leu939Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs45478192 16:23635348-23635348 16:23624027-23624027
22 PALB2 NM_024675.3(PALB2): c.3428T> A (p.Leu1143His) single nucleotide variant Conflicting interpretations of pathogenicity rs62625284 16:23614913-23614913 16:23603592-23603592
23 PALB2 NM_024675.3(PALB2): c.1756G> A (p.Asp586Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587781954 16:23641719-23641719 16:23630398-23630398
24 PALB2 NM_024675.3(PALB2): c.3307G> C (p.Val1103Leu) single nucleotide variant Uncertain significance rs201657283 16:23619228-23619228 16:23607907-23607907
25 PALB2 NM_024675.3(PALB2): c.968C> A (p.Ala323Glu) single nucleotide variant Uncertain significance rs730881882 16:23646899-23646899 16:23635578-23635578
26 PALB2 NM_024675.3(PALB2): c.187C> T (p.Leu63Phe) single nucleotide variant Uncertain significance rs730881899 16:23649195-23649195 16:23637874-23637874
27 PALB2 NM_024675.3(PALB2): c.1526G> A (p.Gly509Asp) single nucleotide variant Uncertain significance rs786203176 16:23646341-23646341 16:23635020-23635020
28 PALB2 NM_024675.3(PALB2): c.1316G> T (p.Gly439Val) single nucleotide variant Uncertain significance rs537258442 16:23646551-23646551 16:23635230-23635230
29 PALB2 NM_024675.3(PALB2): c.1115G> C (p.Ser372Thr) single nucleotide variant Uncertain significance rs786204243 16:23646752-23646752 16:23635431-23635431
30 PALB2 NM_024675.3(PALB2): c.3247G> A (p.Glu1083Lys) single nucleotide variant Uncertain significance rs747785029 16:23619288-23619288 16:23607967-23607967
31 PALB2 NM_024675.3(PALB2): c.3428T> C (p.Leu1143Pro) single nucleotide variant Uncertain significance rs62625284 16:23614913-23614913 16:23603592-23603592
32 PALB2 NM_024675.3(PALB2): c.1348A> C (p.Asn450His) single nucleotide variant Uncertain significance rs62625274 16:23646519-23646519 16:23635198-23635198
33 PALB2 NM_024675.3(PALB2): c.2897T> C (p.Ile966Thr) single nucleotide variant Uncertain significance rs587780214 16:23634389-23634389 16:23623068-23623068
34 PALB2 NM_024675.3(PALB2): c.2869A> C (p.Lys957Gln) single nucleotide variant Uncertain significance rs515726103 16:23634417-23634417 16:23623096-23623096
35 PALB2 NM_024675.3(PALB2): c.2473A> G (p.Arg825Gly) single nucleotide variant Uncertain significance rs745747228 16:23641002-23641002 16:23629681-23629681
36 PALB2 NM_024675.3(PALB2): c.1222T> C (p.Tyr408His) single nucleotide variant Uncertain significance rs515726064 16:23646645-23646645 16:23635324-23635324
37 PALB2 NM_024675.3(PALB2): c.1759G> A (p.Ala587Thr) single nucleotide variant Uncertain significance rs1060502733 16:23641716-23641716 16:23630395-23630395
38 PALB2 NM_024675.3(PALB2): c.2026A> C (p.Ile676Leu) single nucleotide variant Uncertain significance rs761478794 16:23641449-23641449 16:23630128-23630128
39 PALB2 NM_024675.3(PALB2): c.1340C> A (p.Ala447Glu) single nucleotide variant Uncertain significance rs1555461334 16:23646527-23646527 16:23635206-23635206
40 PALB2 NM_024675.3(PALB2): c.2515-24A> G single nucleotide variant Likely benign rs515726089 16:23640620-23640620 16:23629299-23629299
41 PALB2 NM_024675.3(PALB2): c.2590C> T (p.Pro864Ser) single nucleotide variant Benign/Likely benign rs45568339 16:23637715-23637715 16:23626394-23626394
42 PALB2 NM_024675.3(PALB2): c.2014G> C (p.Glu672Gln) single nucleotide variant Benign/Likely benign rs45532440 16:23641461-23641461 16:23630140-23630140
43 PALB2 NM_024675.3(PALB2): c.1572A> G (p.Ser524=) single nucleotide variant Benign/Likely benign rs45472400 16:23646295-23646295 16:23634974-23634974
44 PALB2 NM_024675.3(PALB2): c.1194G> A (p.Val398=) single nucleotide variant Benign/Likely benign rs61755173 16:23646673-23646673 16:23635352-23635352
45 PALB2 NM_024675.3(PALB2): c.2993G> A (p.Gly998Glu) single nucleotide variant Benign/Likely benign rs45551636 16:23634293-23634293 16:23622972-23622972
46 PALB2 NM_024675.3(PALB2): c.2794G> A (p.Val932Met) single nucleotide variant Benign/Likely benign rs45624036 16:23635370-23635370 16:23624049-23624049
47 PALB2 NM_024675.3(PALB2): c.3300T> G (p.Thr1100=) single nucleotide variant Benign/Likely benign rs45516100 16:23619235-23619235 16:23607914-23607914
Sources

Expression for Pancreatic Cancer 3

About this section
Search GEO for disease gene expression data for Pancreatic Cancer 3.
Sources

Pathways for Pancreatic Cancer 3

About this section
Sources

GO Terms for Pancreatic Cancer 3

About this section

Biological processes related to Pancreatic Cancer 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 8.96 PALB2 GDNF
2 embryonic organ development GO:0048568 8.62 PALB2 GDNF
Sources

Sources for Pancreatic Cancer 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....